Clinical trials: Comparison of the Efficacy
Diabetes Mellitus, Diabetes Mellitus, Type 1
A Novel mHealth Application Guided by an Optimization Algorithm for T1D Sensor-Augmented Insulin Injection Users
The Artificial Pancreas lab at McGill University has developed an optimization algorithm for adults with Type 1 Diabetes (T1D) on Multiple Daily Injection (MDI) therapy with the adjunctive use of glucose sensor technology…
- Trial name
- NCT04123054
- Testing
- Mobile App, Mobile App + Basal-Bolus Optimization Algorithm
- Where
- 2 sites in Canada
- Volunteers
- 84 people
- Sponsor
- McGill University
Migraine, Common Migraine
A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine
The purpose of this study is to evaluate the safety and efficacy of two doses of topiramate (100 and 200 mg daily) versus placebo and propranolol in the prevention of migraine.
- Conditions
- Migraine, Common Migraine, Classic Migraine, Headache
- Trial name
- NCT00236561
- Testing
- topiramate, propranolol
- Volunteers
- 786 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join.
- Trial name
- NCT07754461
- Testing
- Survodutide
- Where
- 101 sites in United States, Australia and 3 more
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorder
MDD POC Study GSK372475 Subjects Depressive Disease
To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.
- Trial name
- NCT00420641
- Testing
- GSK372475, Paroxetine
- Where
- 33 sites in Bulgaria, Canada and 8 more
- Volunteers
- 492 people
- Sponsor
- GlaxoSmithKline
Pain
Caldolor Versus Caldolor Plus OFIRMEV in Total Knee or Hip Arthroplasty Surgeries
The objective of this study is to compare the effectiveness and of perioperative use of Caldolor alone and in combination with OFIRMEV in total knee or hip arthroplasty procedures.
- Trial name
- NCT01773005
- Testing
- Ofirmev, Caldolor
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Anita Gupta
Visible Light Exposure on Healthy Back Skin
Determine the Photoprotection Efficacy of Seven Sunscreen Products Under Visible Light Exposure.
To evaluate the protective effect of seven sunscreens on the pigmentation caused by visible light in comparison to an untreated control zone in healthy volunteers.
- Trial name
- NCT06796179
- Testing
- Visible Light Exposure - Treated zones with sunscreen products, Visible Light Exposure - Untreated zone
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Hypertension
LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension
This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.
- Trial name
- NCT01373086
- Testing
- LFF269, Eplerenone
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times…
- Trial name
- NCT00239473
- Testing
- 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
- Where
- 38 sites in Germany, Italy and 2 more
- Volunteers
- 429 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST2 (NCT00877383)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 176 sites in United States, Canada and 7 more
- Volunteers
- 1,142 people
- Sponsor
- Novartis Pharmaceuticals
Pain, Joint, Knee Arthropathy
Comparison Of The Analgesic Efficacy Of IPACK (Interspace Between The Popliteal Artery And Capsule Of The Posterior Knee) Block Alone And IPACK Block Combined With Genicular Block In Patients Planned For Total Knee Arthroplasty
The IPACK (interspace between the popliteal artery and capsule of the posterior knee) block is a regional anesthesia technique in which a local anesthetic is infiltrated under ultrasound guidance between the popliteal artery and…
- Conditions
- Pain, Joint, Knee Arthropathy, Anesthesia, Orthopedic Disorder
- Trial name
- NCT06065878
- Testing
- IPACK + Genicular Nerve Block
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Cenk Gacemer
Anesthesia, Catheter Blockage
The Efficacy of Continuous Femoral Nerve Catheter Orifice Configuration for Postoperative Analgesia in Knee Arthroplasty
Femoral nerve catheter for postoperative analgesia will be included in the adult patients undergoing total knee arthroplasty included in the study.
- Conditions
- Anesthesia, Catheter Blockage, Knee Arthropathy, Pain, Postoperative
- Trial name
- NCT04202250
- Testing
- CEMP (closed-ended multiport catheter) group, OESP (open-ended single port catheter) group
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Gulhane School of Medicine
Chemotherapy-Induced Neutropenia
Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)
A Phase III Randomized Controlled Open Label Comparative Multicentric Trial To Compare The Safety And Efficacy of Indigenous Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) With Neupogen In Patients on…
- Trial name
- NCT00776165
- Testing
- Recombinant Human GCSF (Shantha Biotechnics Limited), Neupogen
- Where
- 7 sites in India
- Volunteers
- 126 people
- Sponsor
- Shantha Biotechnics Limited
Metastatic Pancreatic Cancer
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
This study plans to enroll participants with previously treated metastatic pancreatic cancer and harbor centrally confirmed KRAS G12D mutation.
- Trial name
- NCT07262567
- Testing
- GFH375, Chemotherapy
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Chronic Troublesome Sialorrhea, Cerebral Palsy
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
The objective of this study is to investigate the efficacy and safety of NT 201 compared with placebo for the treatment of chronic troublesome sialorrhea associated with neurological disorders (e.g.
- Conditions
- Chronic Troublesome Sialorrhea, Cerebral Palsy, Stroke, Traumatic Brain Injury
- Trial name
- SIPEXI (NCT02270736)
- Testing
- NT 201
- Where
- 31 sites in Georgia, Hungary and 4 more
- Volunteers
- 256 people
- Sponsor
- Merz Pharmaceuticals GmbH
Major Depressive Disorder
Exergames-acceptance and Commitment Therapy Program for Treatment of Major Depressive Disorder
Background: The prevalence of depressive disorder, particularly major depressive disorder is on the rise globally and the use of antidepressant medication for treatment does not usually resulting in full remission.
- Trial name
- NCT05812001
- Testing
- Exergames-acceptance and commitment therapy (e-ACT), Acceptance and commitment therapy (ACT)
- Volunteers
- 120 people
- Sponsor
- Universiti Sains Malaysia
Chronic Hepatitis B
Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B
The outcome of treatment of chronic hepatitis B is determined by viral and host interaction, thus the combination therapy of immunomodulator (PEG-IFN) and potent antiviral drug (entecavir) should improve the response rate.
- Trial name
- NCT01243281
- Testing
- PEG-IFN and entecavir
- Where
- Thailand
- Volunteers
- 126 people
- Sponsor
- Chulalongkorn University
Obsessive-Compulsive Disorder
Alternative Treatment to Reduce Chronicity in OCD: Research Into Brain Response and Adequacy of Treatment
Rationale: Obsessive-Compulsive Disorder (OCD) is a disabling neuropsychiatric disorder that often has a chronic disease course.
- Trial name
- arrIBA (NCT03929081)
- Testing
- Inference Based Approach (IBA), Cognitive Behavioural Therapy (CBT)
- Where
- 7 sites in Netherlands
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- GGZ Centraal
Epilepsy, Major Depressive Disorder (MDD)
Lethargic Depression Study
This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.
- Trial name
- NCT00064467
- Testing
- Extended-release bupropion (HCl)
- Where
- 24 sites in United States
- Volunteers
- 268 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
This is a randomized, double-blind, double-dummy, active-controlled, multi-center study to assess the efficacy and safety of abrocitinib 200 mg (2 x 100 mg tablets) administered orally QD compared with dupilumab 300 mg…
- Trial name
- NCT04345367
- Testing
- Abrocitinib 200 mg, Dupilumab 300 mg
- Where
- 151 sites in United States, Australia and 13 more
- Volunteers
- 727 people
- Sponsor
- Pfizer
Relapsing-remitting Multiple Sclerosis
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
- Trial name
- NCT05906992
- Testing
- CT-P53, US-Ocrevus, EU-Ocrevus
- Where
- Poland
- Volunteers
- 512 people
- Sponsor
- Celltrion
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.